RA Capital Management Reaffirms 33% Stake in Climb Bio, Appoints New Board Member
CLYM has more than doubled off its 52-week low of $1.21.
Summary
RA Capital Management maintains its 33.0% stake in Climb Bio and updates its board representation, signaling continued strong investor commitment.
Key Events · Ownership and Investor Activity · CLYM
-
Beneficial Ownership Maintained
RA Capital Management, L.P. and its affiliates continue to beneficially own 23,249,186 shares, representing 33.0% of Climb Bio's common stock. This follows their previous increase to 33.0% reported on April 29, 2026.
-
Board Representation Change
Dr. Breanna Celebi, an Analyst of RA Capital, was appointed to Climb Bio's Board of Directors, replacing Dr. Andrew Levin, effective June 29, 2026. Both individuals are associated with RA Capital.
-
Internal Share Distribution
Sera Medicines, LLC, an entity associated with RA Capital, distributed 2,479,872 shares of common stock to its members, including RA Capital Healthcare Fund and RA Capital Nexus Fund III, on July 2, 2026. This was an internal reallocation and not a market transaction.
Analysis · CLYM · Life Sciences
RA Capital Management, a significant institutional investor, has reaffirmed its 33.0% beneficial ownership in Climb Bio. This filing also details a change in their board representation, with Dr. Breanna Celebi replacing Dr. Andrew Levin. This indicates continued strong commitment and active involvement from RA Capital, a key investor in the company.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 29.8% of the 1910 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.15%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CLYM was trading at $13.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $768.5M. The 52-week trading range was $1.21 to $14.42. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.